Sinovant gains Chinese rights to Angion's BB3

Angion Biomedica Corp. (Uniondale, N.Y.) granted Sinovant Sciences Ltd. (Beijing, China) exclusive rights to develop, commercialize and manufacture BB3 in China, including Hong Kong and Macau, and Taiwan.

Angion will receive an upfront payment and is eligible for regulatory and commercial milestones as well as royalties. The partners will jointly develop BB3 in delayed graft function (DGF) and acute kidney injury (AKI), with Sinovant taking the lead in the licensed territories. ...